The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CYP3A inhibitors and adverse outcomes in patients treated with docetaxel chemotherapy.
Paul L. Swiecicki
No relevant relationships to disclose
Pamela J. Atherton
No relevant relationships to disclose
Heidi D. Finnes
No relevant relationships to disclose
Suneetha Puttabasavaiah
No relevant relationships to disclose
Matthew P. Goetz
No relevant relationships to disclose